NCT07096063 - Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk | Biotech Hunter

Enrollment

887,132

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

July 15, 2025

Study Completion Date

July 15, 2025

Conditions

Type 2 DiabetesOverweightCardiovascular (CV) Risk

Interventions

DRUG

Tirzepatide

New use of tirzepatide dispensing claim is used as the exposure.

DRUG

Dulaglutide

New use of dulaglutide dispensing claim is used as the comparator.

DRUG

Semaglutide

New use of semaglutide dispensing claim is used as the exposure/comparator.

DRUG

Sitagliptin

New use of sitagliptin dispensing claim is used as the comparator.

Trial Locations (1)

Brigham and Women's Hospital, Boston

All Listed Sponsors

lead

Brigham and Women's Hospital

OTHER